Genome-Edited Progenitor Cells for HbF Without Foreign Transgenes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hemoglobinopathies such as sickle cell anemia and β-thalassemia are limited in effectiveness and safety, with gene therapy approaches facing challenges like insertional oncogenesis and transgene silencing, necessitating the development of safer and more effective methods to increase fetal hemoglobin production.
Innovation Solution
Genome editing using DNA endonucleases to introduce double-strand breaks in specific loci within the δβ-globin region of chromosome 11, causing deletions or inversions to enhance γ-globin expression and increase fetal hemoglobin levels, thereby reducing the expression of harmful hemoglobin variants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gene therapy approaches are used to increase fetal hemoglobin production, then therapeutic effectiveness is improved, but safety deteriorates due to insertional oncogenesis and transgene silencing
Solution Approach 1:
The invention extracts and removes the harmful β-globin gene or regulatory elements that suppress γ-globin expression through precise genome editing. By using CRISPR-Cas9 or similar technologies to create targeted double-strand breaks and induce deletions or inversions, the harmful components are excised from the genome, thereby increasing fetal hemoglobin production without introducing foreign transgenes that could cause insertional oncogenesis or silencing
Solution Approach 2:
The invention replaces the mechanical gene therapy approach (introducing foreign DNA) with a genome editing approach that modifies existing genomic structures. Instead of adding transgenes that may be silenced or insert into oncogenic sites, the system uses programmable nucleases to precisely edit endogenous genes, substituting a more controlled and safer mechanism for the problematic mechanical insertion method
2Ease of operation
If current treatments for hemoglobinopathies are administered, then symptom management is provided, but treatment limitations and side effects persist
Solution Approach 1:
The invention performs preliminary action by correcting the underlying genetic defect before it causes severe symptoms or requires chronic management. By administering genome-edited cells that permanently increase fetal hemoglobin production, the treatment addresses the root cause rather than merely managing symptoms, thereby providing both immediate relief and long-term curative potential
Solution Approach 2:
The invention changes the fundamental parameter of hemoglobin composition by permanently increasing fetal hemoglobin levels through genome editing. This parameter change transforms the disease state from one requiring chronic symptom management to one where the underlying pathology is corrected, thereby improving both ease of operation and treatment reliability simultaneously
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively increases fetal hemoglobin levels, ameliorating symptoms of hemoglobinopathies by reducing the harmful effects of sickle-shaped red blood cells and unpaired alpha-globin chains, offering a safer and more durable therapeutic option.
Implementation Method 1
Genome editing using DNA endonucleases to introduce double-strand breaks in specific loci within the δβ-globin region of chromosome 11
Data Source
AI summary
The present application provides materials and methods for treating hemoglobinopathies. More specifically, the application provides methods for producing progenitor cells that are genetically modified via genome editing to increase the production of fetal hemoglobin (HbF), as well as modified progenitor cells (including, for example, CD34+ human hematopoietic stem cells) producing increased levels of HbF, and methods of using such cells for treating hemoglobinopathies such as sickle cell anemia and β-thalassemia.